I agree Suzuki. They are definitely worried in my opinion of the competition risk posed by Oncosil. They have a vested interest in casting doubt and talking the stock down. As to the sample size they keep banging on about, that was set by BSI. BSI asked for supplementary data for 20 patients. Oncosil delivered 42 patient data. Double what was asked by BSI. So, what they are talking about is completely false and misleading as it applies to Oncosil.
OSL Price at posting:
7.6¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)